Taysha Gene Therapies, Inc.
Taysha Gene Therapies, Inc. scores highest on Anchor (56) and lowest on Price (21). Its PosiPenta is 40.74 out of 100, around the middle of similar companies.
On the Penta Grid this week, Taysha Gene Therapies, Inc. is Grid #516 of 836 in the Healthcare sector in United States, and Grid #2,818 of 3,999 in United States.
Compared with similar companies in the Healthcare sector in United States.
The five pillars
Similar companies
| Company | PosiPenta | P | E | N | T | A |
|---|---|---|---|---|---|---|
| Taysha Gene Therapies, Inc. | 40.74 | 21 | 41 | 37 | 48 | 56 |
| Damora Therapeutics, Inc. | 44.93 | 27 | 35 | 55 | 56 | 52 |
| InnovAge Holding Corp. | 61.51 | 13 | 87 | 74 | 56 | 77 |
| Nektar Therapeutics | 36.68 | 35 | 29 | 27 | 52 | 41 |
| U.S. Physical Therapy, Inc. | 64.09 | 23 | 88 | 91 | 56 | 63 |
| LB Pharmaceuticals Inc | 46.96 | 19 | 38 | 78 | 60 | 40 |
Similar-sized companies in the same sector, this week. P Price · E Earnings · N Nitro · T Torque · A Anchor.
Details
PPrice
| P/E ratio | -8.83 |
| P/B ratio | 3.05 |
EEarnings
| Trailing EPS | ₹-38.83 |
| Forward EPS | ₹-43.81 |
NNitro
| Price | 342.87 |
| 52-week high | 691.42 |
| 52-week low | 327.24 |
| Fall from 52-week high | 50.4% |
TTorque
| Return on equity (ROE) | -47.05% |
| Debt-to-equity | 0.15 |
AAnchor
| Beta (price swings) | 1.17 |
| Market cap | ₹11,171 Cr |
| Insider holding | 9.45% |
| Dividend yield | 0.00% |
Figures as used for the week of 17 Oct 2026; today's figures on the company page may differ slightly.
Questions
What is Taysha Gene Therapies, Inc.'s PosiPenta score?
Taysha Gene Therapies, Inc.'s PosiPenta is 40.74 out of 100 for the week of 17 Oct 2026, based on 5 of 5 pillars.
Where does Taysha Gene Therapies, Inc. stand on the Penta Grid?
On the Penta Grid this week, Taysha Gene Therapies, Inc. is Grid #516 of 836 in the Healthcare sector in United States, and Grid #2,818 of 3,999 in United States.
Which PosiPenta pillar is strongest for Taysha Gene Therapies, Inc.?
Anchor (stability and dividends), with a score of 56 out of 100: around the middle of similar companies.
Which PosiPenta pillar is weakest for Taysha Gene Therapies, Inc.?
Price (valuation), with a score of 21 out of 100: weaker than most similar companies.
Has Taysha Gene Therapies, Inc.'s PosiPenta changed since last week?
Yes, it rose 4.13 points, from 36.61 to 40.74.
PositoAI is for research and education only and is not investment advice.